APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-20

Price

$134.75

+0.03%

This is the 2026-08-20 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score13.0Top Tier

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading as a pure merger arbitrage play following AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The exceptionally low realized volatility of 1.6% and technical signals like QUIET_STORM and STEADY_CLIMB perfectly reflect the stock's mechanical drift toward this final buyout price. Furthermore, the current RISK_ON macro regime and exceptionally tight credit spreads (0.81%) provide supreme institutional confidence that the $10.9 billion acquisition will close in Q3 2026 without financing or regulatory friction.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONSELLER FATIGUE

Key Takeaways

Actionable Thesis: APGE is a pinned merger arbitrage asset, with its price action anchored to the pending $135.11/share all-cash acquisition by AbbVie [1.2.4].
Key Risk: The primary risk is a regulatory block (e.g., FTC antitrust concerns) which would shatter the $134.09 technical floor.
What to Watch: Monitor for final regulatory approvals and shareholder votes leading up to the expected Q3 2026 deal closure.

← Back to 2026-08-20 View Full APGE History →Yahoo Finance &nearr;